Craig Hallum initiated coverage on Quince Therapeutics with a new price target
Stocks in this Quantisnow insightHealth Care
Historical context for QNCX
Across the 14 sessions after earlier QNCX headlines, the stock closed higher 7 times and lower 7 times, with a median move of 11.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | QNCX | SPY |
|---|---|---|---|
| Aug 14, 2026 | Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update | +5.0% | -0.2% |
| Jul 29, 2026 | Oppenheimer initiated coverage on Quince Therapeutics with a new price target | +13.6% | -1.5% |
| Jun 30, 2026 | Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board | -1.2% | +0.8% |
| Jun 24, 2026 | Leerink Partners initiated coverage on Quince Therapeutics with a new price target | -1.7% | -0.0% |
| Jun 23, 2026 | Cantor Fitzgerald initiated coverage on Quince Therapeutics with a new price target | +4.4% | -1.5% |
| May 18, 2026 | UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILDand 2 other headlines that session | -13.5% | -0.1% |
Quantisnow market dataNASDAQ
QNCX
Quince Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2019
Get push alerts for QNCX
Full QNCX profile on Quantisnow Follow QNCX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time